- Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
-
Dae-ha Kim, Gee ho Min, Dong-won Lee, Ke Ryun Ahn, Ji Hye Kim, Snag-Jun Suh, Young Kul Jung, Hyung Joon Yim
-
J Liver Cancer. 2016;16(1):57-62. Published online March 31, 2016
-
DOI: https://doi.org/10.17998/jlc.16.1.57
-
-
 Abstract
 PDF
- Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the
vascular endothelial growth factor receptor intracellular kinase pathway and is the first
agent to demonstrate a statistically significant improvement in overall survival for patients
with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or
complete response reported in the previous studies. We herein report a case of dramatic
partial response in a patient who had advanced HCC with multiple lung metastasis and portal
vein thrombosis treated with sorafenib.
|
E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Follow JLC on Twitter